Skip to main content

Get the latest news from world and India’s leading pharmaceutical companies Pharma Industry, pharmaceutical marketing, generic drugs, and Complete news for Pharmacy and Life Sciences professionals.

  • WHO Declares Ebola Outbreak in Congo and Uganda a Global Health Emergency

    The World Health Organization has officially declared the ongoing Ebola outbreak in the Democratic Republic of the Congo and Uganda a “Public Health Emergency of International Concern” (PHEIC), raising global alarm over the rapid spread of the deadly virus across Central Africa.

  • US Opens Door for Pharma Companies to Escape 100% Tariffs Through Manufacturing Shift
    US Opens Door for Pharma Companies to Escape 100% Tariffs Through Manufacturing Shift

    The U.S. Department of Commerce has launched a new application process that could allow pharmaceutical companies to significantly reduce looming Section 232 tariffs if they commit to moving drug manufacturing operations to the United States.

  • Eisai Bets Big on Alzheimer’s Drug Leqembi as Sales Forecast Nears 1 Billion USD
    Eisai Bets Big on Alzheimer’s Drug Leqembi as Sales Forecast Nears 1 Billion USD
    Japanese drugmaker Eisai is projecting strong commercial growth for its Alzheimers therapy Leqembi, signaling growing confidence in the global adoption of disease-modifying treatments for early Alzheimer’s disease.
  • FDA Approves Genentech’s Tecentriq for Precision-Guided Bladder Cancer Treatment
    FDA Approves Genentech’s Tecentriq for Precision-Guided Bladder Cancer Treatment

    Genentech has announced that the U.S. Food and Drug Administration (FDA) has approved Tecentriq and Tecentriq Hybreza for the adjuvant treatment of adults with muscle-invasive bladder cancer (MIBC) who show circulating tumor DNA molecular residual disease (ctDNA MRD) after bladder removal surgery. The approval marks the first FDA-cleared ctDNA-guided therapy approach for this aggressive cancer type.

  • FDA launches major push to repurpose existing drugs for rare and chronic diseases
    FDA launches major push to repurpose existing drugs for rare and chronic diseases

    The U.S. Food and Drug Administration (FDA) has announced a new initiative aimed at accelerating the repurposing of already approved medicines to treat diseases with significant unmet medical needs, including rare disorders, neurodegenerative diseases, metabolic conditions, and substance use disorders.

  • OneSource Specialty Pharma Limited reports strong Q4 FY26 recovery, reaffirms FY28 growth guidance
    OneSource Specialty Pharma Limited reports strong Q4 FY26 recovery, reaffirms FY28 growth guidance

    OneSource Specialty Pharma Limited has announced a strong recovery in its fourth quarter performance for FY26, driven by growth across all major business segments and the commercial launch of semaglutide products in India. The company also reaffirmed its FY28 guidance of achieving nearly USD 400 million in organic revenue with around 40% EBITDA margin.

  • Biogen Completes acquisition of Apellis Pharmaceuticals
    Biogen Completes acquisition of Apellis Pharmaceuticals

    -- Biogen Inc. (Nasdaq: BIIB) today announced the successful completion of the acquisition of Apellis Pharmaceuticals, Inc. (Nasdaq: APLS). Apellis, a leader in advancing treatments for serious, complement-driven diseases, is now a wholly owned subsidiary of Biogen.

  • GLP-1 Obesity Drugs May Reduce Fat While Preserving Muscle, Study Finds
    GLP-1 Obesity Drugs May Reduce Fat While Preserving Muscle, Study Finds
    A new real-world study presented at the European Congress on Obesity 2026 suggests that popular obesity medications such as semaglutide and tirzepatide may help patients lose mostly fat while preserving much of their muscle mass.
  • Heart Attack Survivors May Face Faster Memory Decline, New Study Warns
    Heart Attack Survivors May Face Faster Memory Decline, New Study Warns

    People who have survived a heart attack could be at a greater risk of experiencing faster declines in memory and thinking abilities as they age, according to a new study published in the journal Stroke.

    Researchers found that adults with a prior heart attack had a significantly higher likelihood of developing cognitive impairment over time compared to individuals without a history of heart attack. The findings highlight a growing connection between heart health and brain health, especially among older adults.

  • FDA Approves BeOne’s BEQALZI for Blood Cancer
    FDA Approves BeOne’s BEQALZI for Blood Cancer
    BeOne Medicines Ltd. a global oncology company, today announced that the U.S. Food and Drug Administration (FDA) has granted accelerated approval to BEQALZI™ (bee-KAHL-zee; sonrotoclax), a foundational, next-generation BCL2 inhibitor, for the treatment of adult patients with relapsed or refractory (R/R) mantle cell lymphoma
Subscribe to Pharma News